For media inquiries: Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219
March 17, 2025
Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg
February 6, 2025
Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn’s and Colitis Congress®
November 7, 2024
Mozart Therapeutics Announces Publication of MTX-101 Preclinical Data Demonstrating Modulation of Regulatory CD8 T Cell Network to Restore Immune Homeostasis
More news Releases
